January 21, 2020 | English | عربي
Add to Twitter
 
GNT Pharma's Anti-dementia Drug 'crisdesalazine' Demonstrates Efficacy in Phase III Clinical Study with Companion Dogs with Dementia
• Crisdesalazine demonstrated significant improvement in cognition function in the primary outcome measure

• Crisdesalazine demonstrated significant improvement in dementia in the secondary outcome measures